Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
everolimus + vinorelbine
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Everolimus + vinorelbine is a combination of two small molecule anticancer drugs used primarily in the treatment of advanced or metastatic breast cancer, particularly HER2-positive cases that are resistant to trastuzumab and have been pre-treated with taxanes. Everolimus is an mTOR (mechanistic target of rapamycin) inhibitor that blocks a key signaling pathway involved in cell growth, proliferation, and survival. Vinorelbine is a semi-synthetic vinca alkaloid that inhibits microtubule assembly, thereby disrupting mitosis and inducing apoptosis in rapidly dividing cells. The combination targets multiple pathways to overcome resistance mechanisms and improve therapeutic outcomes. Clinical trials have also explored this combination for other cancers such as renal cell carcinoma[3][5][6].
- Brand names
- NavelbineAfinitor
- Other names
- vinorelbine tartrateRAD001RAD-001RAD 001
02
Targets
Mechanistic target of rapamycin complex 1TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on everolimus + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on everolimus + vinorelbine.